Head to Head Comparison: Aytu BioPharma (NASDAQ:AYTU) vs. Zealand Pharma A/S (OTCMKTS:ZLDPF)

Aytu BioPharma (NASDAQ:AYTU) and Zealand Pharma A/S (OTCMKTS:ZLDPF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Risk & Volatility

Aytu BioPharma has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Institutional and Insider Ownership

33.5% of Aytu BioPharma shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Aytu BioPharma and Zealand Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Zealand Pharma A/S	68.82%	41.80%	38.49%

Valuation and Earnings

This table compares Aytu BioPharma and Zealand Pharma A/S”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$56.60 million	0.41	-$13.56 million	($4.58)	-0.47
Zealand Pharma A/S	$1.40 billion	2.29	$977.29 million	$13.48	3.32

Zealand Pharma A/S has higher revenue and earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Aytu BioPharma and Zealand Pharma A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1	1	3	0	2.40
Zealand Pharma A/S	0	5	0	3	2.75

Aytu BioPharma presently has a consensus target price of $9.83, suggesting a potential upside of 357.36%. Given Aytu BioPharma’s higher probable upside, research analysts clearly believe Aytu BioPharma is more favorable than Zealand Pharma A/S.

Summary

Zealand Pharma A/S beats Aytu BioPharma on 11 of the 15 factors compared between the two stocks.

About Aytu BioPharma

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.